Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 30 papers were listed this time. Here's a handful in our areas of our research interest:
Crespin DJ, Federspiel JJ, Biddle AK, et al. Ticagrelor versus Genotype-Driven Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Value Health. 2011 Jun;14(4):483-91. Epub 2011 May 19. PubMed PMID: 21669373.
Hayes AJ, Clarke PM, Voysey M, Keech A. Simulation of Quality-Adjusted Survival in Chronic Diseases: An Application in Type 2 Diabetes. Med Decis Making. 2011 Jun 2. [Epub ahead of print] PubMed PMID: 21636740.
Woodhall SC, Jit M, Soldan K, et al; on behalf of the QOLIGEN study group. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sex Transm Infect. 2011 Jun 2. [Epub ahead of print] PubMed PMID: 21636616.
Biggs SA, Duarte RV, Raphael JH, et al. Influence of a latent period in QALY anaylsis: Pilot study of intrathecal drug delivery systems for chronic non-malignant pain. Br J Neurosurg. 2011 Jun;25(3):401-6. Epub 2011 Feb 28. PubMed PMID: 21355772.
Kondo M, Hoshi SL, Yamanaka T, et al. Economic evaluation of the 21-gene signature (Oncotype DX(®)) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Res Treat. 2011 Jun;127(3):739-49. Epub 2010 Nov 17. PubMed PMID: 21082239.
